HPC
CLBT icon

HM Payson & Co’s Cellebrite CLBT Stock Holding History

HM Payson & Co’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-120
Closed -$2.16K – 1146
2025
Q4 		$2.16K Buy
+120
New +$2.15K ﹤0.01% 1049

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

HM Payson & Co's CLBT Position: Q1 2026 in Review

HM Payson & Co sold out of Cellebrite (CLBT) in Q1 2026, closing a stake of 120 shares — an estimated $2.16K sold.

HM Payson & Co first reported a position in CLBT in Q4 2025 and held it in 1 quarter. The position peaked at $2.16K in Q4 2025. 221 funds tracked by Wall St. Rank hold CLBT as of Q1 2026.

  • HM Payson & Co reported no remaining Cellebrite position as of Q1 2026 after selling out during the quarter.
  • HM Payson & Co sold 120 Cellebrite shares in Q1 2026, an estimated $2.16K.
  • HM Payson & Co first reported a position in Cellebrite in Q4 2025 and held it in 1 quarter.
  • HM Payson & Co's Cellebrite position peaked at $2.16K in Q4 2025.
  • 221 funds tracked by Wall St. Rank held Cellebrite as of Q1 2026.

Based on HM Payson & Co's 13F filing for Q1 2026, filed 13 Apr 2026.